General
Preferred name
CLAVULANIC ACID
Synonyms
CLAVULANATE LITHIUM ()
BRL 14151 ()
MM-14151 ()
MM 14151 ()
RX-10100 ()
MM14151 ()
BRL14151 ()
BRL-14151 ()
Clavulanate potassium salt ()
Clavulanate ()
Clavulanate+Amoxicillin ()
clavulanic acid, Rexahn ()
Clavulanate (potassium) ()
CLAVULANATE POTASSIUM ()
Clavulanate (potassium salt) ()
BRL-14151K ()
Clavulanate potassium component of augmentin ()
Clavulanate potassium component of timentin ()
BRL 14151K ()
Clavulanate potassium component of clavulox ()
Potassium clavulanate ()
Serdaxin ()
Acide clavulanique ()
Acido clavulanico ()
P&D ID
PD009731
CAS
61177-45-5
58001-44-8
1365254-41-6
Tags
covalent binder
natural product
drug
nuisance
available
Approved by
FDA
First approval
1984
Drug indication
Infectious disease
infection
Bacterial infection
Drug Status
vet_approved
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Clavulanic acid is a β-lactamase inhibitor that was isolated from Streptomyces clavuligerus . It is used in combination with β-lactam antibacterials and does not have inherent antibacterial activity. Clavulanic acid can overcome antibacterial resistance in bacteria that secrete β-lactamase. Included in the WHO Essential Medicines list as the mixture of amoxicillin + clavulanic acid (co-amoxiclav). (GtoPdb)
DESCRIPTION Clavulanic acid is a naturally occurring powerful bacterial ¦Â-lactamases inhibitor for research of infections caused by bacteria, including infections of the ears. Clavulanic acid is active against a wide spectrum of gram-positive and gram-negative bacterias[1].
PRICE 29
DESCRIPTION Clavulanic Acid(RX-10100), a major beta-lactam antibiotic produced by the organism Streptomyces claveris, is a potent bacterial beta-lactamase inhibitor used in the study of infections caused by bacteria. Clavulanic Acid has a broad spectrum of biological activity and is active against a wide variety of Gram-positive and Gram-negative bacteria. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
24
Cayman Chemical Bioactives
19456
ChEMBL Approved Drugs
CHEMBL1003
CHEMBL777
ChEMBL Drugs
CHEMBL1003
CHEMBL777
CovalentInDB
CI000182
CovBinderInPDB
CBR000737
CBR001580
CBR002509
CBR002510
CBR002512
CBR002513
CBR002933
CBR004362
CBR004363
Drug Repurposing Hub
DrugBank
DB00766
DrugBank Approved Drugs
DB00766
DrugCentral
669
DrugCentral Approved Drugs
669
DrugMAP
DMAJNYM
DM2FGRT
DrugMAP Approved Drugs
DM2FGRT
Guide to Pharmacology
11128
Mcule NIBR MoA Box Subset
MCULE-3963000692
MedChem Express Bioactive Compound Library
HY-A0256A
HY-A0256
NCATS Inxight Approved Drugs
23521W1S24
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
clavulanic-acid
TargetMol Bioactive Compound Library
T19860
External IDs
78
Properties
(calculated by RDKit )
Molecular Weight
199.05
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
0
cLogP
-1.1
TPSA
87.07
Fraction CSP3
0.5
Chiral centers
2.0
Largest ring
5.0
QED
0.55
Structural alerts
1
Beta lactamase inhibition
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology/virology
Anti-infection
Member status
member
MOA
beta-Lactamase Inhibitors
beta lactamase inhibitor
Indication
otitis
Therapeutic Class
Antibiotics
Target
antibiotic
Bacterial
Beta-lactamase
¦Â-Lactamase
β-Lactamase
Fungal
Source data